Helix Biomedix Inc.

Rodan & Fields, LLC

Timothy John Falla

Lijuan Zhang

Scott M Harris

Kathy Ann Fields

Kathryn Pregerson Rodan

George Paul Majewski

Dzung Q Le

Robert Bianchini

The compositions of the various embodiments include benzoyl peroxide and Hest G-18-0. The methods of this invention include treating acne, increasing the solubility of benzoyl peroxide, and treating the skin. Embodiments are also directed to a dual chamber package comprising a chamber for benzoyl peroxide and a chamber for Hest G-18-0.

Hest G-18-0 and benzoyl peroxide compositions and methods for using the same

This disclosure is directed to compositions comprised of retinaldehyde, one or more skin conditioning agents, and, optionally, one or more additional retinoids. This disclosure is directed. Embodiments are also directed to compositions comprised of retinaldehyde, one or more peptides, one or more skin conditioning agents, one or more calcium containing agents, and, optionally, one or more additional retinoids. Embodiments are also directed to compositions comprised of retinaldehyde, one or more peptides, one or more skin conditioning agents, one or more calcium containing agents, and, optionally, one or more additional retinoids. Additional embodiments disclose methods for treating the skin wherein a characteristic of the skin is improved, the characteristics include firmness, elasticity, fine lines and wrinkles, skin texture, dullness, dyschromia, skin tone, reduction or elimination of acne, and any combination thereof. This disclosure is also directed to kits used for treating the skin with the compositions described herein.

Retinaldehyde containing compositions and methods of use

Embodiments herein are directed to moisturizing compositions comprising interpenetrating polymer networks, methods of making moisturizing compositions and methods of using moisturizing compositions.

Moisturizing compositions and uses thereof

Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.

Peptide fragments for inducing synthesis of extracellular matrix proteins

The invention relates to small molecules having biological and therapeutic activity. Particularly, the invention relates to small molecules having lipolytic and anti-adipogenic activity. Two examples of such molecules are 4-methyl-2-(octanoylamino) pentanoic acid and N-isopentyloctanamide. The invention further relates to methods of preventing or treating skin conditions such as cellulite using small molecules having lipolytic and anti-adipogenic activity.

N-acyl amino acid derivatives for treating skin conditions such as cellulite

Short peptides having biological and therapeutic activity are disclosed. Specifically, the activity of the disclosed peptides is directed to reducing or protecting against mutagen-induced cellular/tissue toxicity (i.e., chemopreventive). For example, the disclosed peptides protect against skin toxicity and/or mutagenesis that occurs from ultraviolet (UV) light exposure. The disclosed peptides also block the activation of certain cell cycle regulatory proteins such as Chk2. An example of such a peptide is Ser-Leu-Tyr-Gln-Ser (SEQ ID NO: 10). The disclosed peptides are also useful for methods of reducing or protecting against cellular toxicity and mutation accumulation that would otherwise occur following mutagen exposure. One such method is drawn to applying a peptide to the skin to prevent or reduce mutagenic damage resulting from UV light (e.g., sunlight) exposure.

Peptide protection against ultraviolet light toxicity

The disclosed invention provides tetrapeptides with the amino acid sequence proline-glutamine-glutamate-X (P-Q-E-X), where X can be either lysine (K) or isoleucine (I). These tetrapeptides inhibit ultraviolet light (UV)-induced expression of the pro-inflammatory cytokine interleukin-6 (IL-6) by skin epithelial cells and fibroblasts. Furthermore, the tetrapeptides repress the upregulation of matrix metalloproteinase-1 (MMP-1) by skin fibroblasts induced by either direct exposure to UV rays or treatment with media conditioned by UV-treated keratinocytes. The small size and bio-activity of the tetrapeptides render them suitable for use in therapies directed to inflammatory skin disorders and as active ingredients in skin care products.

Protective skin care peptides

Peptides having four to fourteen residues are disclosed that possess biological activity. These peptides constitute short fragments of the peptide HB-107 (SEQ ID NO:1), which itself is a fragment of the antimicrobial protein cecropin B, and exhibit cell stimulatory, migratory and anti-inflammatory properties. As keratinocytes are especially sensitive to these effects, the disclosed peptides comprise a useful agent for the medical treatment of injury to the skin, such as from diabetic ulcers. The peptides also are effective in preventing and reversing skin surface damage resulting from various environmental insults. Importantly, the therapeutic effects of the peptides manifest at concentrations equal to or greater than those of peptide HB-107, and thus represent a less expensive, more versatile means for developing effective therapies. Methods for the production and use of these peptides are also disclosed.

Short bio-active peptides for cellular and immunological modulation

The invention encompasses hexapeptides consisting of alternating hydrophobic residues (B) at positions 2, 4, and 6, hydrophilic, charged residues (X) at positions 1 and 3, and a naphthylalanine (Nal), an aliphatic or aromatic residue (O) at position five, represented generally by the formula XBXBOB, which exhibit antimicrobial activity against infections caused by a variety of pathogens. These pathogens may include gram positive or negative bacteria, acid-fast bacteria such as mycobacteria, parasites, dermatophytes, or fungal pathogens. Typical fungal pathogens includeand typical dermatophytes includeand. The hexapeptides of the present invention exhibit antifungal activity, antibacterial activity, desirable stability, and lack toxicity to the mammal receiving treatment.

Growing community of inventors

Woodinville, WA, United States of America

Timothy John Falla